{"id":3420,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1996-05-23","marketCap":14110.2,"name":"Neurocrine Biosciences Inc","phone":"18586177600","outstanding":99.51,"symbol":"NBIX","website":"https://www.neurocrine.com/","industry":"Biotechnology"},"price":141.11,"year":2024,"month":5,"day":2,"weekday":"Thursday","title":"Analysis of Corporate Governance and Leadership in Neurocrine Biosciences Inc Stock's Performance","date":"2024-05-02","url":"/posts/2024/05/02/NBIX","content":[{"section":"Introduction","text":"Neurocrine Biosciences Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for neurological and endocrine-related disorders. In analyzing the stock performance of Neurocrine Biosciences Inc, it is important to consider the influence of corporate governance and leadership on the company's achievements and investor confidence."},{"section":"Effect of Strong Corporate Governance","text":"Neurocrine Biosciences Inc's strong corporate governance practices have played a significant role in shaping its stock performance. The company's commitment to transparency, accountability, and proper risk management has instilled investor confidence, attracting long-term shareholders and favorable capital market support."},{"section":"Case Study: Leadership Transition","text":"A case study on Neurocrine Biosciences Inc's leadership transition highlights the impact of effective leadership on stock performance. In 2018, the company appointed Dr. Kevin Gorman as the CEO, bringing extensive industry experience and a strong track record of success. Under Dr. Gorman's leadership, Neurocrine Biosciences Inc witnessed significant advancements in its drug development pipeline, leading to positive clinical trial results and investor optimism. This, in turn, positively influenced the stock performance."},{"section":"Case Study: Shareholder Engagement","text":"Another case study demonstrates the importance of shareholder engagement in Neurocrine Biosciences Inc's stock performance. The company has implemented shareholder-friendly practices, such as regular communication channels, annual shareholder meetings, and active response to investor concerns. This approach has facilitated a positive relationship between the company and its shareholders, fostering trust and loyalty, and ultimately contributing to a stable and favorable stock performance."},{"section":"Importance of Ethical Leadership","text":"Ethical leadership practices are crucial in maintaining Neurocrine Biosciences Inc's stock performance. The company's commitment to high ethical standards in clinical research, drug development, and business operations has helped build a strong reputation and trust within the industry. Ethical leadership instills investor confidence and mitigates regulatory risks, ensuring sustainable growth and positive stock performance."},{"section":"Conclusion","text":"Corporate governance and leadership have a significant impact on Neurocrine Biosciences Inc's stock performance. Strong corporate governance practices, effective leadership transitions, shareholder engagement, and ethical leadership contribute to investor confidence, fostering positive stock performance. Through these case studies, it becomes evident that Neurocrine Biosciences Inc's commitment to sound governance and impactful leadership plays a pivotal role in its overall success."},{"section":"References:","text":"Insert references here"}],"tags":["LongSignals","Long","Biotechnology"],"news":[{"category":"company","date":1714611715,"headline":"Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements","id":127370022,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine Biosciences Reports Robust Financial Performance and Pipeline Progress","url":"https://finance.yahoo.com/news/neurocrine-biosciences-inc-nbix-q1-010155745.html"},{"category":"company","date":1714594696,"headline":"Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech","id":127360641,"image":"https://media.zenfs.com/en/ibd.com/7217117115b95a37a00b4a5740f71a8a","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine stock rose Wednesday after the leading biotech topped Wall Street's sales expectations and wrapped a key regulatory filing.","url":"https://finance.yahoo.com/m/10101846-5f86-33db-abed-0e845d0a6e8d/why-things-are-looking-up-for.html"},{"category":"company","date":1714570221,"headline":"Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say","id":127360643,"image":"https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","symbol":"NBIX","publisher":"Yahoo","summary":"Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.","url":"https://finance.yahoo.com/news/neurocrine-nbix-reports-q1-earnings-133021037.html"},{"category":"company","date":1714568656,"headline":"No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win","id":127350297,"image":"https://media.zenfs.com/en/ibd.com/0a36ee0f18bca8e1e3e845322c51abdc","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine stock jumped early Wednesday after the company's biggest moneymaker, Ingrezza, topped first-quarter sales forecasts.","url":"https://finance.yahoo.com/m/10101846-5f86-33db-abed-0e845d0a6e8d/no.-1-biotech-stock.html"},{"category":"company","date":1714567090,"headline":"Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript","id":127352303,"image":"","symbol":"NBIX","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4688065-neurocrine-biosciences-inc-nbix-q1-2024-earnings-call-transcript"},{"category":"company","date":1714565706,"headline":"Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates","id":127350299,"image":"https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?","url":"https://finance.yahoo.com/news/neurocrine-biosciences-nbix-q1-earnings-121506644.html"},{"category":"company","date":1714565160,"headline":"Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences","id":127372553,"image":"","symbol":"NBIX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3471516266"},{"category":"company","date":1714564080,"headline":"Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle","id":127372554,"image":"","symbol":"NBIX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3471484389"},{"category":"company","date":1714561200,"headline":"Neurocrine Biosciences Reports First Quarter 2024 Financial Results","id":127350301,"image":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.","url":"https://finance.yahoo.com/news/neurocrine-biosciences-reports-first-quarter-110000344.html"},{"category":"company","date":1714561080,"headline":"NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024","id":127372556,"image":"","symbol":"NBIX","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3471396208"},{"category":"company","date":1714560960,"headline":"Buy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising Pipeline","id":127372557,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3472876293"},{"category":"company","date":1714548000,"headline":"Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Charles River Labs (CRL) and Neurocrine (NBIX)","id":127354529,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3471054715"},{"category":"company","date":1714547948,"headline":"Neurocrine: Q1 Earnings Snapshot","id":127346309,"image":"","symbol":"NBIX","publisher":"Finnhub","summary":"SAN DIEGO — SAN DIEGO — Neurocrine Biosciences Inc. on Wednesday reported first-quarter earnings of $43.4 million. The San Diego-based company said it had profit of 42 cents per share. ...","url":"https://finnhub.io/api/news?id=ff9c40b911ab3ba40fdf9750fbc82b64fbfbf0d6d66d19a9afdb98194bdd4762"},{"category":"company","date":1714547940,"headline":"Neurocrine’s Hold Rating Affirmed Amid Earnings Shortfall and Steady Sales Outlook","id":127372559,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3471053515"},{"category":"company","date":1714544220,"headline":"Neurocrine backs FY24 INGREZZA net product sales view $2.1B-$2.2B","id":127372565,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3470976536"},{"category":"company","date":1714544160,"headline":"Neurocrine reports Q1 adjusted EPS $1.20, consensus $1.01","id":127372566,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3470975600"},{"category":"company","date":1714544100,"headline":"Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M","id":127372568,"image":"","symbol":"NBIX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3470972882"},{"category":"company","date":1714513703,"headline":"UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval","id":127339774,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"NBIX","publisher":"Yahoo","summary":"The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tuesday.  Huntington's disease is an inherited condition that causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability.  Ingrezza was first approved in 2017 in its oral capsule formulation to treat adults with movement disorders tardive dyskinesia and chorea.","url":"https://finance.yahoo.com/news/1-neurocrine-biosciences-huntingtons-disease-214823158.html"},{"category":"company","date":1714511520,"headline":"Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules","id":127339775,"image":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing.","url":"https://finance.yahoo.com/news/neurocrine-biosciences-announces-u-fda-211200223.html"},{"category":"company","date":1714499303,"headline":"Neurocrine Biosciences' Huntington's disease drug gets FDA approval","id":127329721,"image":"","symbol":"NBIX","publisher":"Finnhub","summary":"The U.S. Food and DrugAdministration has approved the granule formulation ofNeurocrine Biosciences' INGREZZA drug to treat movementdisorders associated with Huntington's disease, the company...","url":"https://finnhub.io/api/news?id=10fa8cbf8b42afdadc5096a9d04f38cabaf46f2fb4f38bf26f9f7f3bea89ba9d"},{"category":"company","date":1714498286,"headline":"FDA approves Neurocrine Biosciences' Huntington's disease drug","id":127329300,"image":"","symbol":"NBIX","publisher":"Finnhub","summary":"The U.S. Food and DrugAdministration has approved granule formulation ofNeurocrine Biosciences' drug to treat movementdisorders associated with Huntington's disease, the company saidon...","url":"https://finnhub.io/api/news?id=253009b9f6b833dd9ca8ea7361dab9e36b38238d289ebf17518f57b60610c025"},{"category":"company","date":1714482924,"headline":"Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics","id":127339776,"image":"https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","symbol":"NBIX","publisher":"Yahoo","summary":"Beyond analysts' top -and-bottom-line estimates for Neurocrine (NBIX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.","url":"https://finance.yahoo.com/news/curious-neurocrine-nbix-q1-performance-131524337.html"},{"category":"company","date":1714474440,"headline":"Neurocrine Biosciences Q1 2024 Earnings Preview","id":127323474,"image":"","symbol":"NBIX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3469326007"},{"category":"company","date":1714470660,"headline":"Notable earnings before Wednesday's open","id":127320292,"image":"","symbol":"NBIX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3469230469"},{"category":"company","date":1714455840,"headline":"Fly Intel: After-Hours Movers","id":127332008,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3470018424"},{"category":"company","date":1714450560,"headline":"Neurocrine announces FDA approval of INGREZZA SPRINKLE capsules","id":127372572,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3469854321"},{"category":"company","date":1714446720,"headline":"Neurocrine management to meet with Oppenheimer","id":127372573,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3469735518"},{"category":"company","date":1714403333,"headline":"AbbVie: The Inevitable Is Happening","id":127299286,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg?io=getty-c-w1536","symbol":"NBIX","publisher":"SeekingAlpha","summary":"AbbVie's shares dropped last week due to concerns about Humira erosion and despite ABBV beating revenue and EPS expectations. Find out why ABBV stock is a Buy.","url":"https://seekingalpha.com/article/4687271-abbvie-the-inevitable-is-happening"},{"category":"company","date":1714369980,"headline":"RBC Capital Remains a Hold on Neurocrine (NBIX)","id":127296834,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3467049368"},{"category":"company","date":1714097760,"headline":"Promising Outlook for Neurocrine’s NBI-‘845 in MDD Market Based on Strong Phase 2 Results and Competitive Positioning","id":127258954,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463008070"},{"category":"company","date":1714094220,"headline":"Buy Rating Affirmed for Neurocrine on Promising Phase 2 SAVITRI Study Results","id":127258955,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3462962254"},{"category":"company","date":1714093980,"headline":"Maintaining Hold on Neurocrine Amid Promising Yet Uncertain Clinical Developments","id":127258956,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3462958251"},{"category":"company","date":1714069724,"headline":"Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data","id":127225910,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1726209248/image_1726209248.jpg?io=getty-c-w1536","symbol":"NBIX","publisher":"SeekingAlpha","summary":"Neurocrine achieved positive results achieved from phase 2 SAVITRI study for the treatment of patients with MDD. Check out why NBIX stock is a strong buy.","url":"https://seekingalpha.com/article/4686417-neurocrine-success-continues-to-roll-in-with-positive-mdd-treatment-data"},{"category":"company","date":1714040585,"headline":"Neurocrine Biosciences Launches WHAT THE C@H Educational Initiative to Support Congenital Adrenal Hyperplasia Community","id":127212076,"image":"","symbol":"NBIX","publisher":"Finnhub","summary":"SAN DIEGO - Neurocrine Biosciences, Inc. today announced the launch of WHAT THE C@H!, an educational initiative that aims to close the gap in the need for helpful information about congenital...","url":"https://finnhub.io/"},{"category":"company","date":1713967298,"headline":"Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth","id":127199159,"image":"","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","url":"https://finance.yahoo.com/news/neurocrine-biosciences-nbix-reports-next-140138122.html"},{"category":"company","date":1713961800,"headline":"Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community","id":127199161,"image":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition.","url":"https://finance.yahoo.com/news/neurocrine-biosciences-launches-c-h-123000719.html"},{"category":"company","date":1713960000,"headline":"3 Red-Hot Biotech Rockets Blasting Off in 2024","id":127317116,"image":"https://media.zenfs.com/en/investorplace_417/9f0765f187fa6bf56b6956db834ceeeb","symbol":"NBIX","publisher":"Yahoo","summary":"The economy is currently on a stable trajectory and is poised for sustained growth; the indicators show a positive outlook overall. However, the biotech industry presents even more compelling potential, demonstrating a compounding annual growth rate (CAGR) of 13.96% from 2024 to 2030. This substantial growth is largely attributed to robust government support and the expanding field of personalized medicine, which creates ample opportunities for innovation and advancement. These pivotal factors e","url":"https://finance.yahoo.com/news/3-red-hot-biotech-rockets-120000355.html"},{"category":"company","date":1713956640,"headline":"Neurocrine Biosciences upgraded at Wells Fargo on pipeline","id":127188631,"image":"","symbol":"NBIX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459363371"},{"category":"company","date":1713947820,"headline":"Tesla, Airbnb upgraded: Wall Street's top analyst calls","id":127184326,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459146689"},{"category":"company","date":1713941820,"headline":"Jefferies Sticks to Its Buy Rating for Neurocrine (NBIX)","id":127189698,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459014721"},{"category":"company","date":1713941460,"headline":"Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)","id":127185391,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459008487"},{"category":"company","date":1713940260,"headline":"Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)","id":127189591,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3458986241"},{"category":"company","date":1713939180,"headline":"Neurocrine launches CAH community website ahead of FDA filing","id":127223971,"image":"","symbol":"NBIX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3460107086"},{"category":"company","date":1713937260,"headline":"Wall Street Analysts Are Neutral on Top Healthcare Picks","id":127189701,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3458933380"},{"category":"company","date":1713936120,"headline":"Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)","id":127185392,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3458916079"},{"category":"company","date":1713933780,"headline":"Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)","id":127185393,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3458882001"},{"category":"company","date":1713898593,"headline":"Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?","id":127164967,"image":"https://media.zenfs.com/en/ibd.com/8597a36beb8fae692b538c535df786c7","symbol":"NBIX","publisher":"Yahoo","summary":"Top-notch biotech stock Neurocrine surged Tuesday after analysts suggested the company's depression treatment could rival ketamine.","url":"https://finance.yahoo.com/m/235205c4-0efa-328a-a8bb-ba90313bdb70/does-neurocrine%2C-the-no.-1.html"},{"category":"company","date":1713871320,"headline":"Neurocrine scores surprise win with depression drug","id":127164968,"image":"https://www.biopharmadive.com/imgproxy/y0ub_IItWfvzG6gsDykNc1MNSLlrotQ-Gi5Z899LHd0/g:ce/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTEyNTQ3MzA0NzRfMEN6a1VnZi5qcGc.webp","symbol":"NBIX","publisher":"Yahoo","summary":"Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.","url":"https://www.biopharmadive.com/news/neurocrine-depression-study-medicine-takeda-results/714001/"},{"category":"company","date":1713870000,"headline":"Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder","id":127156465,"image":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","symbol":"NBIX","publisher":"Yahoo","summary":"Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be","url":"https://finance.yahoo.com/news/neurocrine-biosciences-reports-positive-phase-110000471.html"},{"category":"company","date":1713864600,"headline":"Neurocrine NBI-1065845 results 'look potentially promising,' says RBC Capital","id":127167280,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457393738"},{"category":"company","date":1713861720,"headline":"Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Neurocrine (NBIX) and Medtronic (MDT)","id":127167282,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457331052"},{"category":"company","date":1713858060,"headline":"Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)","id":127161829,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457258150"},{"category":"company","date":1713852540,"headline":"Neurocrine's NBI-1065845 shows efficacy in major depressive disorder","id":127167288,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457160518"},{"category":"company","date":1713843720,"headline":"Wells Fargo upgrades Neurocrine with pipeline 'turning a corner'","id":127167290,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457912448"},{"category":"company","date":1713841800,"headline":"Wells Fargo gets more bullish on Neurocrine, upgrades shares","id":127167292,"image":"","symbol":"NBIX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457863649"},{"category":"company","date":1713835860,"headline":"Neurocrine succeeds in mid-stage trial for Takeda-partnered depression drug","id":127167294,"image":"","symbol":"NBIX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457721093"},{"category":"company","date":1713835200,"headline":"Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Carisma Therapeutics (CARM)","id":127167296,"image":"","symbol":"NBIX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3457705348"},{"category":"company","date":1713798659,"headline":"10 Best Performing Biotech ETFs in 2024","id":127137943,"image":"https://media.zenfs.com/en/insidermonkey.com/8577738f84a3c852cf540caf7ca4aba5","symbol":"NBIX","publisher":"Yahoo","summary":"In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]","url":"https://finance.yahoo.com/news/10-best-performing-biotech-etfs-151059372.html"}]}